Conatus Pharmaceuticals

Conatus Pharmaceuticals is focused on the development of human therapeutics to treat liver failures and cancer.

Conatus Pharmaceuticals is a privately-held biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. Their lead program, CTS-1027, is currently undergoing Phase 2 clinical trials for the treatment of Hepatitis C Virus (HCV). Conatus licensed CTS-1027 from Hoffmann-La Roche in 2006, and to date its development has been the primary focus of the Company.